ClinicalTrials.gg
Active, not recruitingNCT07146022Updated Aug 17, 2026

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

A Phase 3 interventional study of VDPHL01 QD and Placebo in Androgenetic Alopecia (AGA), Androgenetic Alopecia and AGA, sponsored by Veradermics, Inc.. Active, not recruiting at 71 sites in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Veradermics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
9th of 203
552 · median 40
Started
2025
with 19 others
Phase 3
14 of 216
2 open now
Primary completion
2027-06
later than 39 of 62 live
Registered
198th of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 9th largest by planned enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 39 of the 62 other live ones, and was the 198th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).

AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

Read the detailed description

Not required.

03

Conditions studied

  • Androgenetic Alopecia (AGA)
  • Androgenetic Alopecia
  • AGA
  • Female Androgenetic Alopecia
  • Hair Loss

Browse trials for

Keywords

  • Androgenetic Alopecia
  • AGA
  • Hair Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a female aged 18-65 years old;
  • Subject has a clinical diagnosis of mild to moderate AGA;
  • Subject is in good general health and has adequate renal and hepatic function;
  • Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;
  • Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English;
  • Subject is willing and able to swallow study drug whole;
  • Subject agrees to have a micro dot tattoo placed on their scalp;
  • Subject agrees to have this area photographed at study visits as indicated in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has uncontrolled blood pressure or orthostatic hypotension;
  • Subject has symptoms or history of certain heart or thyroid conditions;
  • Subject has a history of or active hair loss due to conditions/diseases other than AGA;
  • Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;
  • Subject has been diagnosed with COVID-19 within 16 weeks of baseline;
  • Subject has had previous radiation of the scalp;
  • Use of any of the following treatments within the indicated before screening:

    • Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening
    • Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening
    • Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening
    • Subject has used systemic cimetidine, ketoconazole, diazoxide, or (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening
    • Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, rich plasma within 6 months prior to screening
    • Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening
    • Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;
    • Subject has any other condition that, in the investigator's opinion, interfere with the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
552 participants (estimated)

Study arms

  • Experimental
    VDPHL01 BID

    VDPHL01 will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will continue VDPHL01 BID for an additional 6 months.

    Drug: VDPHL01 BID

  • Experimental
    VDPHL01 QD and Placebo QD

    Placebo will be taken orally once a day (QD) in the AM or PM. VDPHL01 will be taken orally once a day (QD) in the AM or PM for the first 6 months of the study. After month 6, subject will continue this same dose regimen for an additional 6 months.

    Drug: VDPHL01 QD · Drug: Placebo

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 BID

    Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 BID group, and take VDPHL01 orally twice a day (BID), once in the AM and once in the PM for an additional 6 months.

    Drug: Placebo

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 QD and Placebo QD

    Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 QD and Placebo QD group, and take placebo orally once a day in the AM or PM; VDPHL01 will be taken orally once a day in the AM or PM for an additional 6 months.

    Drug: Placebo

Interventions

  • VDPHL01 Extended Release (ER) Tablet

  • DrugPlacebo

    Placebo tablet

  • VDPHL01 Extended Release (ER) Tablet

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Changes in non-vellus Target Area Hair Counts (TAHC)

    Changes from baseline in non-vellus TAHC using digital image analysis at Month 6.

    Time frame: Month 6

  2. Subjects Evaluation of Treatment Benefit

    Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.

    Time frame: Month 6

07

Study locations

71 sites
  • Site 73
    Birmingham, Alabama 35209, United States
  • Site 89
    Birmingham, Alabama 35244, United States
  • Site 77
    Phoenix, Arizona 85006, United States
  • Site 30
    Fort Smith, Arkansas 72916, United States
  • Site 69
    Encino, California 91436, United States
  • Site 2
    Fremont, California 94538, United States
  • Site 64
    Manhattan Beach, California 90266, United States
  • Site 93
    Northridge, California 91324, United States
  • Site 66
    Santa Monica, California 90404, United States
  • Site 34
    Sherman Oaks, California 91403, United States
  • Site 94
    Thousand Oaks, California 91320, United States
  • Site 21
    Vista, California 92083, United States
  • Site 5
    Castle Rock, Colorado 80109, United States
  • Site 24
    Greenwood Village, Colorado 80111, United States
  • Site 17
    Aventura, Florida 33180, United States
  • Site 71
    Boca Raton, Florida 33486, United States
  • Site 86
    Coral Gables, Florida 33134, United States
  • Site 62
    Coral Gables, Florida 33146, United States
  • Site 99
    Miami, Florida 33173, United States
  • Site 54
    Ocala, Florida 34470, United States
  • Site 43
    Atlanta, Georgia 30329, United States
  • Site 90
    Sandy Springs, Georgia 30328, United States
  • Site 31
    Boise, Idaho 83704, United States
  • Site 61
    Chicago, Illinois 60610, United States
  • Site 53
    Clarksville, Indiana 47129, United States
  • Site 15
    Indianapolis, Indiana 46250, United States
  • Site 32
    New Albany, Indiana 47150, United States
  • Site 55
    Plainfield, Indiana 46168, United States
  • Site 27
    West Lafayette, Indiana 47906, United States
  • Site 79
    Leawood, Kansas 66211, United States
  • Site 52
    Louisville, Kentucky 40241, United States
  • Site 41
    Baton Rouge, Louisiana 70809, United States
  • Site 13
    Covington, Louisiana 70433, United States
  • Site 12
    Metairie, Louisiana 70006, United States
  • Site 75
    New Orleans, Louisiana 70124, United States
  • Site 84
    Glenn Dale, Maryland 20769, United States
  • Site 87
    Rockville, Maryland 20850, United States
  • Site 22
    Brighton, Massachusetts 02135, United States
  • Site 80
    Chestnut Hill, Massachusetts 02467, United States
  • Site 59
    Quincy, Massachusetts 02169, United States
  • Site 26
    Clarkston, Michigan 48346, United States
  • Site 68
    Clinton Township, Michigan 48038, United States
  • Site 83
    Southfield, Michigan 48034, United States
  • Site 98
    Medina, Minnesota 55340, United States
  • Site 56
    Minneapolis, Minnesota 55455, United States
  • Site 6
    New Brighton, Minnesota 55112, United States
  • Site 18
    Hackensack, New Jersey 07601, United States
  • Site 37
    Kew Gardens, New York 11415, United States
  • Site 97
    New York, New York 10003, United States
  • Site 82
    Hickory, North Carolina 28602, United States
  • Site 92
    Huntersville, North Carolina 28078, United States
  • Site 39
    Boardman, Ohio 44512, United States
  • Site 72
    Cincinnati, Ohio 45236, United States
  • Site 11
    Columbus, Ohio 43215, United States
  • Site 57
    Portland, Oregon 97210, United States
  • Site 60
    Anderson, South Carolina 29621, United States
  • Site 95
    Hermitage, Tennessee 37076, United States
  • Site 9
    Knoxville, Tennessee 37909, United States
  • Site 4
    Nashville, Tennessee 37215, United States
  • Site 76
    Austin, Texas 78746, United States
  • Site 74
    College Station, Texas 77845, United States
  • Site 67
    Dallas, Texas 75230, United States
  • Site 14
    Houston, Texas 77056, United States
  • Site 88
    San Antonio, Texas 78218, United States
  • Site 91
    Sugar Land, Texas 77479, United States
  • Site 19
    South Jordan, Utah 84095, United States
  • Site 29
    Forest, Virginia 24551, United States
  • Site 63
    Norfolk, Virginia 23502, United States
  • Site 85
    Norfolk, Virginia 23502, United States
  • Site 33
    Burien, Washington 98168, United States
  • Site 70
    Mill Creek, Washington 98012, United States
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — The sponsor is undecided if this information will be shared at this time. This field will be updated when a decision is made.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 28, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jan 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146022
Lead sponsor
Veradermics, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jul 25, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Reid Waldman, M.D.
study chair · Veradermics, Inc.
Timothy Durso, M.D.
study chair · Veradermics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VDPHL01

Start the discussion